This small interfering ribonucleic acid (RNA)[siRNA] therapy is designed to combat one of the ALS subtypes, FUS-ALS, by reducing FUS protein levels. RAG-21 leverages RNA interference (RNAi) technology
The FDA has set a target action date of 18 April 2025 for its decision. If approved, Dupixent is expected to become the first targeted CSU therapy in
This grant will aid the progression of ASHA-624 towards first-in-human clinical trials. Designed using the company’s PRISM drug design technology, it is a brain-penetrant intra-molecular glue inhibitor of
The BLA is sought for treating NSCLC patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) who have received systemic therapies previously. Concurrently, the companies have
The $0.6m (4m yuan) deal, which will facilitate Lakeside’s entry into the medical logistics sector, is set to contribute an estimated $7m in annual revenues to the integrated
ALT-B4 will be used for developing the subcutaneous formulation ENHERTU. As per the agreement, Daiichi Sankyo will gain global rights to utilise Alteogen’s ALT-B4, a human recombinant hyaluronidase
Situated in Milton Park, near Oxford, the new 30,000ft2 facility is part of NEB’s wholly-owned subsidiary network. The site is designed to offer solutions for ambient molecular biology
This partnership leverages SpectronRx’s advanced facilities for late-stage clinical and commercial supplies of the therapy. SpectronRx and Plus Therapeutics collaboration is set to accelerate nuclear medicine and improve
This epinephrine sublingual spray is designed for emergency situations. The FDA’s feedback could potentially lead the company to a New Drug Application (NDA) submission. The FDA-approved epinephrine prodrug
The partnership aims to accelerate the development of new treatments for eye diseases (ophthalmology) and cancer (oncology) as well as enhance the technologies for their production. This deal
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.